The Road To ‘Personalised Medicine’ with AstraZeneca's Duncan McHale
Add bookmark
Duncan McHale, Vice-President for Personalised Healthcare and Biomarkers, Astrazeneca, joins Helen Winsor of Pharma IQ. In this interview he discusses the importance of biomarker discovery & validation, how close we are to ‘Personalised Medicine’, why sample quality is key, the rules of good biobanking, how we can improve biomarker research, what we should change and why, what’s stopping us bringing change and his top 3 priorities for the next 12 months.
